Data / Research funding / Pennsylvania / Research Inst of Fox Chase Can CTR

Research Inst of Fox Chase Can CTR: 96 NIH awards ($120.7M), fiscal years 2021 to 2026

Name: NIH and NSF awards to Research Inst of Fox Chase Can CTR
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

Research Inst of Fox Chase Can CTR in Philadelphia, PA is funded under 96 NIH awards ($120.7M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.

SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.

Get awards like these Watch Research Inst of Fox Chase Can CTR

UEI: FF1XVJMDYVR1
State: Pennsylvania

Awards

96 awards in the window.

Award	Agency	Institute or division	Fiscal year	Amount in window	Start	End	Principal investigator	Source
Molecular Basis for γδ T Lineage Specification	NIH	National Institute of Allergy and Infectious Diseases	2021 to 2025	$8,397,312	May 15, 2014	June 30, 2030	WIEST, DAVID L.	reporter.nih.gov
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIA	NIH	National Cancer Institute	2022 to 2024	$6,227,249	June 15, 2022	May 15, 2025	CLAPPER, MARGIE L.	reporter.nih.gov
Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center	NIH	National Cancer Institute	2022 to 2025	$5,240,348	September 1, 2022	August 31, 2027	CLAPPER, MARGIE L.	reporter.nih.gov
Comprehensive Cancer Center Program at Fox Chase	NIH	National Cancer Institute	2021 to 2025	$5,119,493	July 1, 1997	April 30, 2030	WIEST, DAVID L.	reporter.nih.gov
Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death	NIH	National Institute of Allergy and Infectious Diseases	2021 to 2025	$4,220,934	September 25, 2017	August 31, 2027	BALACHANDRAN, SIDDHARTH	reporter.nih.gov
Regulation of hematopoiesis by ribosomal protein paralogs	NIH	National Institute of Allergy and Infectious Diseases	2021 to 2025	$2,934,669	February 1, 2025	January 31, 2030	WIEST, DAVID L.	reporter.nih.gov
Structural Bioinformatics of Proteins and Protein Complexes and Applications to Cancer Biology	NIH	National Institute of General Medical Sciences	2021 to 2025	$2,925,667	April 1, 2017	March 31, 2028	DUNBRACK, ROLAND L	reporter.nih.gov
Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening	NIH	National Cancer Institute	2021 to 2025	$2,851,879	April 1, 2020	November 30, 2025	FANG, CAROLYN Y.	reporter.nih.gov
Pancreatic cancer-associated fibroblasts: function, detection, and regulation	NIH	National Cancer Institute	2022 to 2025	$2,559,695	June 1, 2022	May 31, 2027	CUKIERMAN, EDNA	reporter.nih.gov
Role of ZBP1 in pathogenesis of Salmonella biofilms	NIH	National Institute of Allergy and Infectious Diseases	2023 to 2025	$2,527,208	May 11, 2023	April 30, 2028	BALACHANDRAN, SIDDHARTH	reporter.nih.gov
Designing selective kinase inhibitors via deep learning	NIH	National Institute of General Medical Sciences	2022 to 2025	$2,379,505	February 1, 2022	November 30, 2026	RINK, LORI	reporter.nih.gov
Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy	NIH	National Cancer Institute	2023 to 2025	$2,239,005	January 1, 2023	December 31, 2027	BALACHANDRAN, SIDDHARTH	reporter.nih.gov
Targeting RIPK3 in Flu-Associated Lung Injury	NIH	National Institute of Allergy and Infectious Diseases	2021 to 2023	$2,222,961	September 18, 2019	August 31, 2025	BALACHANDRAN, SIDDHARTH	reporter.nih.gov
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma	NIH	National Cancer Institute	2021 to 2025	$2,108,871	June 1, 2021	May 31, 2027	YANG, YIBIN	reporter.nih.gov
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms	NIH	National Cancer Institute	2023 to 2025	$2,085,781	July 6, 2023	June 30, 2028	WIEST, DAVID L.	reporter.nih.gov
Reducing Urban Cervical Cancer Disparities Using a Tailored mHealth Intervention to Enhance Colposcopy Attendance	NIH	National Institute on Minority Health and Health Disparities	2023 to 2025	$2,085,056	July 15, 2023	December 31, 2027	MILLER, SUZANNE M	reporter.nih.gov
Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis	NIH	National Cancer Institute	2022 to 2025	$2,082,906	May 11, 2022	April 30, 2027	CLAPPER, MARGIE L.	reporter.nih.gov
Molecular Mechanisms Underlying Adaptor-Mediated Integrin Signaling in a Species-Specific Manner	NIH	National Institute of General Medical Sciences	2022 to 2025	$2,062,158	September 1, 2016	December 31, 2026	WU, JINHUA	reporter.nih.gov
Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy	NIH	National Cancer Institute	2021 to 2025	$2,022,453	April 6, 2021	March 31, 2027	YANG, YIBIN	reporter.nih.gov
Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients	NIH	National Cancer Institute	2021 to 2025	$2,009,718	August 1, 2021	July 31, 2027	ABBOSH, PHILIP	reporter.nih.gov
Neighborhood, social connectedness, and allostatic load	NIH	National Institute on Minority Health and Health Disparities	2023 to 2025	$1,925,841	May 16, 2023	December 31, 2027	FANG, CAROLYN Y.	reporter.nih.gov
Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer	NIH	National Cancer Institute	2022 to 2025	$1,890,097	March 1, 2022	February 28, 2027	JOHNSON, NEIL	reporter.nih.gov
Novel Role of ThPOK in Mammary Carcinoma	NIH	National Cancer Institute	2021 to 2023	$1,880,700	April 3, 2019	March 31, 2025	KAPPES, DIETMAR J	reporter.nih.gov
Deciphering Networks Controlling DNA Amplification	NIH	National Institute of General Medical Sciences	2022 to 2025	$1,870,000	January 1, 2022	November 30, 2026	WHETSTINE, JOHNATHAN R.	reporter.nih.gov
Investigating genetic ancestry influences on oral cavity and laryngeal cancer survival disparities	NIH	National Cancer Institute	2021 to 2023	$1,823,126	March 1, 2019	February 28, 2025	RAGIN, CAMILLE C.	reporter.nih.gov
MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer	NIH	National Cancer Institute	2021 to 2024	$1,672,552	June 1, 2020	May 31, 2026	KRUGER, WARREN D	reporter.nih.gov
Telomerase RNP Prisonbreaks from Phase-Separated Nuclear Body	NIH	National Institute of General Medical Sciences	2023 to 2025	$1,649,252	July 1, 2023	May 31, 2028	CHEN, LU	reporter.nih.gov
Immigrant enclaves: Conferring health advantages or creating health disparities in Chinese immigrants?	NIH	National Institute on Minority Health and Health Disparities	2021 to 2022	$1,584,866	May 2, 2018	December 31, 2024	FANG, CAROLYN Y.	reporter.nih.gov
Examining the Relationship between Residential History at Midlife and Prostate Cancer Outcomes	NIH	National Institute on Minority Health and Health Disparities	2023 to 2025	$1,561,820	August 16, 2023	February 29, 2028	ZEIGLER-JOHNSON, CHARNITA M.	reporter.nih.gov
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development	NIH	National Institute of General Medical Sciences	2021 to 2023	$1,452,865	August 5, 2020	July 31, 2024	JOHNSON, NEIL	reporter.nih.gov
Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer	NIH	National Cancer Institute	2024 to 2025	$1,394,261	August 1, 2023	July 31, 2028	GALLUZZI, LORENZO	reporter.nih.gov
The role of microhomology-mediated end joining in Fanconi anemia pathogenesis	NIH	National Heart, Lung, and Blood Institute	2021 to 2023	$1,389,090	February 1, 2020	January 31, 2024	JOHNSON, NEIL	reporter.nih.gov
Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant Cancers	NIH	National Cancer Institute	2021 to 2025	$1,367,763	September 12, 2017	August 31, 2029	JOHNSON, NEIL	reporter.nih.gov
Extending a Caribbean Based Cohort to Promote US-Caribbean Comparisons to Facilitate Research Addressing Black Health Disparities	NIH	National Institute on Minority Health and Health Disparities	2021 to 2022	$1,336,954	September 1, 2018	March 31, 2025	RAGIN, CAMILLE C.	reporter.nih.gov
Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC)	NIH	National Cancer Institute	2024 to 2025	$1,299,358	August 1, 2024	July 31, 2029	CANADAS, ISRAEL	reporter.nih.gov
Elucidating the critical role of Wee1 in GIST	NIH	National Cancer Institute	2023 to 2025	$1,268,648	March 1, 2023	February 29, 2028	RINK, LORI	reporter.nih.gov
Asian American Community Cohort and Equity Study (ACCESS)	NIH	National Heart, Lung, and Blood Institute	2023 to 2024	$1,255,726	August 15, 2023	July 31, 2025	FANG, CAROLYN Y.	reporter.nih.gov
Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites	NIH	National Cancer Institute	2021 to 2022	$1,225,484	March 1, 2018	February 29, 2024	CLAPPER, MARGIE L.	reporter.nih.gov
Addressing Sexual Concerns in Breast Cancer Survivors: RCT of a Novel Couple-Based Intervention	NIH	National Cancer Institute	2021 to 2022	$1,221,116	September 4, 2018	August 31, 2024	REESE, JENNIFER BARSKY	reporter.nih.gov
Fibroblasts Support the Growth of Brain Metastasis by Rendering Cancer Cells Resistant to Chemotherapy and Inducing Immunosuppression in Tumor Microenvironment	NIH	National Cancer Institute	2023 to 2025	$1,216,874	June 1, 2023	May 31, 2028	YANG, ZENG-JIE	reporter.nih.gov
Interrogating MRCK Protein Kinases in Ovarian Cancer	NIH	National Cancer Institute	2024 to 2025	$1,138,820	March 1, 2024	February 28, 2029	DUNCAN, JAMES STUART	reporter.nih.gov
Hepatic Tissue Integrity and Clonal Fitness: Key Factors in Controlling β-Catenin Induced Oncogenesis	NIH	National Cancer Institute	2024 to 2025	$1,133,540	March 1, 2024	March 2, 2028	FONT-BURGADA, JOAN	reporter.nih.gov
Promoting Effective Clinical Communication about Sexual Health after Gynecologic Cancer: A Randomized Controlled Trial of a Patient-Focused Intervention	NIH	National Cancer Institute	2024 to 2025	$963,919	July 1, 2024	June 30, 2029	REESE, JENNIFER BARSKY	reporter.nih.gov
Mechanistic Studies of Genome Folding	NIH	National Institute of General Medical Sciences	2024 to 2025	$940,000	July 1, 2024	April 30, 2029	LIU, YU	reporter.nih.gov
Interplay between DNA base excision repair and transcriptional regulation	NIH	National Institute of General Medical Sciences	2024 to 2025	$940,000	September 17, 2024	August 31, 2029	WHITAKER, AMY MICHELLE	reporter.nih.gov
Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer	NIH	National Cancer Institute	2024 to 2025	$870,915	May 1, 2022	April 30, 2027	ARORA, SANJEEVANI	reporter.nih.gov
Harnessing ZBP1-driven cell death to improve influenza vaccine efficacy	NIH	National Institute of Allergy and Infectious Diseases	2021	$847,917	August 13, 2021	July 31, 2023	BALACHANDRAN, SIDDHARTH	reporter.nih.gov
Targeting the Rac1 signaling pathway in malignant melanoma	NIH	National Cancer Institute	2021 to 2022	$846,970	April 1, 2018	August 31, 2024	CHERNOFF, JONATHAN	reporter.nih.gov
Harnessing ZBP1-triggered cell death to enhance influenza vaccine responsiveness	NIH	National Institute of Allergy and Infectious Diseases	2023	$833,534	August 7, 2023	July 31, 2024	BALACHANDRAN, SIDDHARTH	reporter.nih.gov
Training Grant in Precision Cancer Control	NIH	National Cancer Institute	2023 to 2025	$775,226	September 14, 2023	August 31, 2028	FANG, CAROLYN Y.	reporter.nih.gov
Repair of Oxidative Damage in G-Quadruplex Promoter DNA	NIH	National Institute of Environmental Health Sciences	2022 to 2024	$747,000	March 6, 2022	February 28, 2025	WHITAKER, AMY MICHELLE	reporter.nih.gov
The role of MER/PROS1 in promoting stromal induced emergence from metastatic melanoma dormancy	NIH	National Cancer Institute	2023 to 2025	$747,000	September 1, 2022	April 30, 2026	FANE, MITCHELL EDWARD	reporter.nih.gov
Asian American Community Cohort and Engagement Study (ACCESS)	NIH	National Heart, Lung, and Blood Institute	2025	$666,328	August 15, 2023	July 31, 2030	FANG, CAROLYN Y.	reporter.nih.gov
Targeting anoctamin 6 to disrupt trogocytosis of cancer-associated fibroblasts	NIH	National Cancer Institute	2025	$642,755	March 7, 2025	February 28, 2030	ASTSATUROV, IGOR	reporter.nih.gov
Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development	NIH	National Cancer Institute	2022 to 2025	$598,357	March 15, 2022	February 28, 2027	CUKIERMAN, EDNA	reporter.nih.gov
Thyroid Hormone Inhibits Medulloblastoma Growth by Inducing Tumor Cell Differentiation	NIH	National Cancer Institute	2025	$559,587	May 1, 2025	April 30, 2030	YANG, ZENG-JIE	reporter.nih.gov
Interrogating Type I Interferon signaling in breast cancer brain metastasis	NIH	National Cancer Institute	2025	$546,142	December 1, 2023	April 30, 2029	CHEN, QING	reporter.nih.gov
The Role of Histone Chaperones in Histone Acetylation and Nucleosome Dynamics	NIH	National Institute of General Medical Sciences	2021 to 2022	$521,170	September 15, 2014	November 30, 2022	ANDREWS, ANDREW JOSEPH	reporter.nih.gov
Characterization of New Allosteric Inhibitors that Disrupt HIV-1 Integrase Dimerization	NIH	National Institute of Allergy and Infectious Diseases	2021 to 2022	$514,250	December 1, 2020	November 30, 2023	ANDRAKE, MARK DAVID	reporter.nih.gov
Neurotransmitter signaling controls stem cell fate	NIH	Eunice Kennedy Shriver National Institute of Child Health & Human Development	2021 to 2022	$514,250	April 15, 2021	March 31, 2024	O'REILLY, ALANA M	reporter.nih.gov
Necroptosis in SARS-CoV-2 pathogenesis, evolution, and therapy	NIH	National Institute of Allergy and Infectious Diseases	2022 to 2023	$513,000	February 1, 2022	January 31, 2024	BALACHANDRAN, SIDDHARTH	reporter.nih.gov
Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer	NIH	National Cancer Institute	2022 to 2023	$511,837	May 1, 2022	April 30, 2024	ARORA, SANJEEVANI	reporter.nih.gov
Defining the molecular basis controlling hematopoietic stem cell symmetric and asymmetric divisions	NIH	National Institute of Diabetes and Digestive and Kidney Diseases	2024 to 2025	$498,000	September 1, 2024	August 31, 2027	LUO, HANZHI	reporter.nih.gov
NPC1 as a novel therapeutic target in ccRCC	NIH	National Cancer Institute	2024 to 2025	$483,395	March 1, 2024	February 28, 2027	KOLENKO, VLADIMIR M	reporter.nih.gov
A novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cancer	NIH	National Cancer Institute	2024	$483,395	June 4, 2024	May 31, 2026	MAKHOV, PETR B.	reporter.nih.gov
Estrogen Suppression as a Strategy to Enhance Immunotherapy Efficacy in EGFR-Mutated Non-Small Cell Lung Cancer	NIH	National Cancer Institute	2024	$483,395	June 1, 2024	May 31, 2026	BODOR, JOSEPH NICHOLAS	reporter.nih.gov
Targeting p300/CBP in renal cell carcinoma	NIH	National Cancer Institute	2025	$483,395	September 1, 2025	August 31, 2027	KOLENKO, VLADIMIR M	reporter.nih.gov
Tumor-specific anti-angiogenic anti-CD70-FGF/VEGF-trap fusion antibodies for renal cancer therapy	NIH	National Cancer Institute	2022 to 2023	$478,122	April 11, 2022	March 31, 2025	MAKHOV, PETR B.	reporter.nih.gov
Building clinically faithful ex vivo indolent lymphoma models for personalized therapy	NIH	National Cancer Institute	2021 to 2022	$476,454	August 17, 2021	July 31, 2024	WANG, Y. LYNN	reporter.nih.gov
A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma	NIH	National Cancer Institute	2023 to 2024	$472,408	July 1, 2023	June 30, 2025	ASTSATUROV, IGOR	reporter.nih.gov
Positive Activities for Asian American Cancer Patients and Caregivers	NIH	National Cancer Institute	2024 to 2025	$471,806	May 13, 2022	March 31, 2027	SHIN-CHO, LILIAN J	reporter.nih.gov
Neoadjuvant Stroma Modification in Pancreatic Cancer	NIH	National Cancer Institute	2021 to 2022	$459,643	August 1, 2021	July 31, 2024	ASTSATUROV, IGOR	reporter.nih.gov
Hepatitis B virus cccDNA	NIH	National Institute of Allergy and Infectious Diseases	2021	$457,500	August 15, 2018	July 31, 2023	SEEGER, CHRISTOPH	reporter.nih.gov
Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways	NIH	National Cancer Institute	2023 to 2024	$454,926	April 1, 2023	March 31, 2026	GOLEMIS, ERICA A.	reporter.nih.gov
Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study	NIH	National Cancer Institute	2025	$429,162	August 1, 2025	July 31, 2027	VIJAYVERGIA, NAMRATA	reporter.nih.gov
Targeting the kinome in K-ras driven colorectal cancers	NIH	National Cancer Institute	2021	$427,763	December 8, 2016	November 30, 2022	DUNCAN, JAMES STUART	reporter.nih.gov
Exploiting vulnerabilities in GIST using novel combination therapies	NIH	National Cancer Institute	2021	$427,763	June 1, 2017	May 31, 2023	RINK, LORI	reporter.nih.gov
Addressing the Training Gap in Oncology on Sexual Health: Development of the Sexual Health Integrative Fellowship Training (SHIFT) Course for Hematology-Oncology Fellows	NIH	National Cancer Institute	2024 to 2025	$323,299	June 1, 2024	May 31, 2026	REESE, JENNIFER BARSKY	reporter.nih.gov
Elucidating the epigenetic regulation of extracellular matrix and virus-induced fibroblast activation	NIH	National Institute of General Medical Sciences	2023 to 2024	$250,000	February 1, 2023	January 31, 2025	GARDINER, JAYE C	reporter.nih.gov
Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer	NIH	National Cancer Institute	2025	$249,000	April 1, 2023	April 30, 2028	FENG, WEIRAN	reporter.nih.gov
Assessment of Efficacy and Toxicity of T3 for Medulloblastoma Treatment	NIH	National Cancer Institute	2025	$219,351	February 1, 2025	January 31, 2027	YANG, ZENG-JIE	reporter.nih.gov
Pancreatic adenocarcinoma secretome as a dynamic biomarker for patient stromal reprogramming efficacy	NIH	National Cancer Institute	2022 to 2023	$188,000	July 8, 2022	June 30, 2024	CAMPBELL, PAUL MICHAEL	reporter.nih.gov
Role of the Parkinson's susceptibility gene LRRK2 in NFAT-mediated malignant mesothelioma tumorigenesis	NIH	National Cancer Institute	2023 to 2024	$188,000	May 1, 2023	April 30, 2026	TESTA, JOSEPH R.	reporter.nih.gov
Divergent Functions of ERK2 Substrate Binding Domains in Pathogenesis of KRAS-Driven Pancreatic Cancer	NIH	National Cancer Institute	2024 to 2025	$188,000	December 13, 2023	November 30, 2025	ASTSATUROV, IGOR	reporter.nih.gov
Comprehensive identification of RAS mutations and allelic co-segregation patterns in colorectal cancer	NIH	National Cancer Institute	2021 to 2022	$187,000	December 14, 2020	November 30, 2023	SEREBRIISKII, ILYA	reporter.nih.gov
Identification of first-in-class epigenetic inhibitors that target Thymine DNA Glycosylase (TDG) for future precision therapy of metastatic melanoma	NIH	National Cancer Institute	2021 to 2022	$187,000	December 1, 2020	November 30, 2023	BELLACOSA, ALFONSO	reporter.nih.gov
Pilot Studies of NN-01-195, a New Tumor-Targeted AURKA Inhibitor	NIH	National Cancer Institute	2025	$186,000	June 23, 2025	May 31, 2027	GOLEMIS, ERICA A.	reporter.nih.gov
Targeting the Unfolded Protein Response in Leukemia Biology and Chemotherapy Resistance	NIH	National Cancer Institute	2021	$163,237	May 7, 2019	August 1, 2021	SYKES, STEPHEN MATTHEW	reporter.nih.gov
Margret B. Einarson, Ph.D., Manager, High Throughput Screening Facility, Fox Chase Cancer Center	NIH	National Cancer Institute	2021	$128,392	September 1, 2019	August 31, 2022	EINARSON, MARGRET B	reporter.nih.gov
The role of cholesterol homeostasis in enzalutamide resistance	NIH	National Cancer Institute	2021	$93,500	December 5, 2019	November 30, 2022	KOLENKO, VLADIMIR M	reporter.nih.gov
Novel anti-CD70-VEGF-trap fusion antibodies as a next-generation therapeutic approach for renal cancer	NIH	National Cancer Institute	2021	$93,500	December 5, 2019	November 30, 2022	MAKHOV, PETR B.	reporter.nih.gov
Systematic study of variations in imaging techniques and response criteria for well differentiated pancreatic neuroendocrine tumors	NIH	National Cancer Institute	2021	$92,150	January 1, 2020	December 31, 2022	VIJAYVERGIA, NAMRATA	reporter.nih.gov
Community to Molecular Approaches in Early Screening and Diagnosis to Promote Equitable Outcomes Through the Continuum of Care in Cancer Among Populations of African Ancestry	NIH	National Cancer Institute	2023	$20,000	September 1, 2023	August 31, 2024	RAGIN, CAMILLE C.	reporter.nih.gov
Addressing Colorectal Cancer-Related Distress: Developing and Evaluating a Couple-Based Mindfulness Intervention	NIH	National Cancer Institute	2022	$4,838	August 12, 2022	October 1, 2022	ZIMMARO, LAUREN A.	reporter.nih.gov
TO Title: Contract Orientation & Kickoff Meeting for Preclinical Services for PREVENT Base IDIQ Title: PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate E	NIH	National Cancer Institute	2024	$3,500	January 25, 2024	January 24, 2029	CLAPPER, MARGIE L.	reporter.nih.gov
ThymUS 2025 International Conference on Lymphopoiesis	NIH	National Institute of Allergy and Infectious Diseases	2025	$3,200	November 15, 2024	October 31, 2025	WIEST, DAVID L.	reporter.nih.gov

Funding by fiscal year

Fiscal year	NIH awards	NIH amount	NSF amount
2025	52	$30,177,234	$0
2024	51	$24,344,442	$0
2023	46	$25,411,583	$0
2022	41	$21,753,573	$0
2021	37	$19,030,040	$0

Open federal funding opportunities

From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.

Open opportunity	Number	Agency	Listing	Closes	Award ceiling	Why it matches
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)	PA-24-254	NIH		July 12, 2027	Not listed	Notice number printed on 1 award here
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)	PAR-27-089	NIH	93.395	November 2, 2026	Not listed	Same assistance listing 93.395 as 27 awards here
Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)	PAR-26-152	NIH	93.395	November 11, 2026	Not listed	Same assistance listing 93.395 as 27 awards here
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)	PAR-27-088	NIH	93.395	November 20, 2026	Not listed	Same assistance listing 93.395 as 27 awards here
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)	PAR-24-214	NIH	93.395	January 7, 2027	$375,000	Same assistance listing 93.395 as 27 awards here
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)	PAR-25-079	NIH	93.395	January 7, 2027	$500,000	Same assistance listing 93.395 as 27 awards here
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	PAR-25-081	NIH	93.395	January 7, 2027	$499,999	Same assistance listing 93.395 as 27 awards here
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)	RFA-CA-27-005	NIH	93.395	January 11, 2027	$700,000	Same assistance listing 93.395 as 27 awards here
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)	PAR-27-009	NIH	93.395	January 25, 2027	Not listed	Same assistance listing 93.395 as 27 awards here
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)	RFA-CA-26-010	NIH	93.395	January 25, 2027	Not listed	Same assistance listing 93.395 as 27 awards here
Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)	RFA-CA-27-003	NIH	93.395	January 25, 2027	Not listed	Same assistance listing 93.395 as 27 awards here
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)	PA-27-100	NIH	93.395	April 5, 2027	Not listed	Same assistance listing 93.395 as 27 awards here
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)	PA-27-102	NIH	93.395	April 5, 2027	Not listed	Same assistance listing 93.395 as 27 awards here
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)	RFA-CA-28-003	NIH	93.395	June 11, 2027	$600,000	Same assistance listing 93.395 as 27 awards here
Successor-in-Interest (Type 6 Parent Clinical Trial Optional)	PA-24-253	NIH	93.395	July 17, 2027	Not listed	Same assistance listing 93.395 as 27 awards here
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)	PA-25-080	NIH	93.395	September 7, 2027	Not listed	Same assistance listing 93.395 as 27 awards here
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)	PAR-24-325	NIH	93.395	September 7, 2027	Not listed	Same assistance listing 93.395 as 27 awards here
Investigator-Focused Award (Parent R35)	PAR-28-037	NIH	93.395	October 4, 2027	Not listed	Same assistance listing 93.395 as 27 awards here
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)	RFA-CA-27-019	NIH	93.395	October 19, 2027	$300,000	Same assistance listing 93.395 as 27 awards here
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)	PAR-27-078	NIH	93.395	October 25, 2027	$375,000	Same assistance listing 93.395 as 27 awards here

Topics of its NIH awards

Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.